What are the indications and survivorship of tumor endoprosthetic reconstructions for patients with extremity metastatic bone disease?
Journal of Surgical Oncology · 2023
DOI: 10.1002/jso.27236 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Surgical Oncology, 2023. Verfasst von Joseph K Kendal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Femoral Neoplasms, Bone Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Background and Objectives Given advances in therapies, endoprosthetic reconstruction (EPR) in metastatic bone disease (MBD) may be increasingly indicated. The objectives were to review the indications, and implant and patient survivorship in patients undergoing EPR for MBD.
Methods
A review of patients undergoing EPR for extremity MBD between 1992 and 2022 at two centers was performed. Surgical data, implant survival, patient survival, and implant failure modes were examined.
Results
One hundred fifteen patients were included with a median follow‐up of 14.9 months (95% confidence interval [CI]: 9.2–19.3) and survival of 19.4 months (95% CI: 13.6–26.1). The most common diagnosis was renal cell carcinoma (34/115, 29.6%) and the most common location was proximal femur (43/115, 37.4%). Indications included: actualized fracture (58/115, 50.4%), impending fracture (30/115, 26.1%), and failed fixation (27/115, 23.5%). Implant failure was uncommon (10/115, 8.7%). Patients undergoing EPR for failed fixation were more likely to have renal or lung cancer ( p = 0.006).
Conclusions
EPRs were performed most frequently for renal cell carcinoma and in patients with a relatively favorable survival. EPR was indicated for failed previous fixation in 23.5% of cases, emphasizing the importance of predictive survival modeling. EPR can be a reliable and durable surgical option for patients with MBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, California, USA.
- Section of Orthopaedic Surgery, Department of Surgery, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Joseph K Kendal
Förderung
- NIAMS NIH HHS
Zitieren
APA
Kendal, J. K., Hamad, C. D., Abbott, A. G., Greig, D., Trikha, R., Christ, A. B., Wessel, L. E., Puloski, S. K. T., Monument, M. J., & Bernthal, N. M. (2023). What are the indications and survivorship of tumor endoprosthetic reconstructions for patients with extremity metastatic bone disease?. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27236
Vancouver
Kendal JK, Hamad CD, Abbott AG, Greig D, Trikha R, Christ AB, et al. What are the indications and survivorship of tumor endoprosthetic reconstructions for patients with extremity metastatic bone disease?. Journal of Surgical Oncology. 2023. doi:10.1002/jso.27236
BibTeX
@article{Kendal2023,
author = {Kendal, Joseph K and Hamad, Christopher D and Abbott, Annalise G and Greig, Danielle and Trikha, Rishi and Christ, Alexander B and Wessel, Lauren E and Puloski, Shannon K T and Monument, Michael J and Bernthal, Nicholas M},
title = {What are the indications and survivorship of tumor endoprosthetic reconstructions for patients with extremity metastatic bone disease?},
journal = {Journal of Surgical Oncology},
year = {2023},
doi = {10.1002/jso.27236}
}
EUVIMED